Lexicon Pharmaceuticals Inc.


Needham Reiterates Buy on Lexicon Pharmaceuticals Inc. Following Phase 3 Results in Type 1 Diabetes

In a research report issued Friday, Needham analyst Alan Carr reiterated a Buy rating on shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) with a price …

Stock Update (NASDAQ:LXRX): Lexicon Pharmaceuticals, Inc. Reports Positive Top-line Results in Pivotal Phase 3 Study for Sotagliflozin in Patients with Type 1 Diabetes

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced that the pivotal in Tandem1 Phase 3 clinical trial of sotagliflozin met its primary endpoint, showing a statistically …

Biotech Beat: Analysts Weigh In on Celldex Therapeutics, Inc. (CLDX) and Lexicon Pharmaceuticals, Inc. (LXRX)

Analysts are weighing in on the development-stage company Celldex Therapeutics, Inc. (NASDAQ:CLDX) and pharmaceutical company Lexicon Pharmaceuticals, Inc.

Company Update (NASDAQ:LXRX): Lexicon Pharmaceuticals, Inc. Reports 3rd Quarter Financial Results and Discusses Collaboration with Sanofi for Sotagliflozin

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) reported financial results for the third quarter ended September 30, 2015 and provided an overview of key milestones for …

Stock Update (NASDAQ:LXRX): Cancer Patients Treated with Lexicon Pharmaceuticals, Inc.’s Telotristat Etiprate Report Improved Function and Well-Being

Lexicon Pharmaceuticals, Inc.’s (NASDAQ:LXRX) telotristat etiprate, the first oral therapy in development for the treatment of carcinoid syndrome (CS), was associated with patient-reported improvements …

Company Update (NASDAQ:LXRX): Lexicon Pharmaceuticals, Inc.’s Telotristat Etiprate Shows Clinical benefit in Treating Carcinoid syndrome in Cancer Patients When Added to Standard of Care

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), telotristat etiprate was shown to have clinical benefit in treating carcinoid syndrome in cancer patients not adequately controlled by …

Wedbush Reiterates Outperform on Lexicon Pharmaceuticals, Inc. Ahead of TELESTAR Presentation at ECC Conference

In a research report released Monday, Wedbush’s healthcare analyst Liana Moussatos reiterated an Outperform rating on shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) with a $19 …

Stock Update (NASDAQ:LXRX): Lexicon Pharmaceuticals, Inc. Announces Sotagliflozin Data to be Presented at European Association for the Study of Diabetes

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced that data from its Phase 2 clinical study of sotagliflozin in type 1 diabetes will be presented in oral …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts